June 19, 2017
1 min read
Save

Spark Therapeutics posts first-quarter net loss of $52.3 million

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Spark Therapeutics reported a net loss of $52.3 million, or $1.70 per share, in the first quarter of 2017 compared with a net loss of $25.6 million, or $0.95 per share, in the first quarter of 2016.

Research and development costs increased from $18.2 million in 2016’s first quarter to $32.7 million this year, which was attributed to an increase in personnel and expenses related to studies to support launch preparation activities for voretigene neparvovec, according to a company press release.

General and administrative expenses for the quarter were $21.4 million compared with $8.9 million in 2016.

The company reported $285.4 million in cash, cash equivalents and marketable securities as of March 31.